Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
about
Treatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesPrognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patientsSequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trialTh1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin.Best practice in the treatment of nonmuscle invasive bladder cancer.Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophilsBladder Cancer Immunotherapy: BCG and Beyond.Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?Immunological basis in the pathogenesis and treatment of bladder cancerThe association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patientsPolarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy.Immunotherapeutic strategies for bladder cancer.The management of BCG failure in non-muscle-invasive bladder cancer: an update.Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.Identification of evidence-based biospecimen quality-control tools: a report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group.Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling.Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2LLocal immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer.Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.
P2860
Q26775541-C2CA1CD9-20D7-4390-997F-4D8316C4766FQ33684090-3DC78DCC-07E6-4C32-9867-3B7E16EC9222Q34979760-505115C5-6383-421C-8EF1-C88A334BF007Q35215350-0A4A2DE2-C64F-46C0-9389-76F3AC70582DQ35245608-77B91E4F-9E32-41FC-AA9C-67BD4F5812A4Q35688392-5AE7086D-6DAB-45AF-970E-65F4BC45E17AQ35689498-8E9FE0FB-5477-4C95-A766-66E94C0EAA98Q36072179-186FB6A2-8639-4850-A089-CF16E174D2F0Q36167778-A19F0EAD-AACD-4A7C-8E77-FD07468E1E82Q36260118-4C490878-AA85-4B20-AB9C-198F83325BD3Q36617483-0B5072C6-B515-460E-9766-50A355E138E9Q36673517-08E737B1-A37C-41FF-AF2C-54BAEC28CAC1Q36977628-9B0157E9-0112-4D1F-BF4A-0F57EE8BC782Q37472576-F597B57D-237B-49C6-8366-0FD7AB2CAEC4Q37791443-54CD3D08-0368-465C-8A92-A512EF94FD4FQ38063697-1DFC52F7-BB06-425C-9E47-AAD5F336B8CAQ39740932-B6D190D7-BD2C-4005-9074-F114AF7811A9Q40305229-2F78D1DA-B81A-4E11-8DF9-E9343A456429Q40545635-63DFDB2E-182C-4D26-AF98-4DEF5FA9E5DEQ40959666-C9BA67DB-548E-481C-A807-1410A4778F19Q42194180-3A538983-64E1-4E59-8F93-D9AF56BC52E0Q43904333-F12CCBBB-CE76-47CF-B5EE-7D17D1BE652FQ54792101-7AB4507F-54AE-46C5-BCCB-1F0F0B2DD2DF
P2860
Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Urinary cytokines during intra ...... tability and prognostic value.
@en
Urinary cytokines during intra ...... tability and prognostic value.
@nl
type
label
Urinary cytokines during intra ...... tability and prognostic value.
@en
Urinary cytokines during intra ...... tability and prognostic value.
@nl
prefLabel
Urinary cytokines during intra ...... tability and prognostic value.
@en
Urinary cytokines during intra ...... tability and prognostic value.
@nl
P2093
P1476
Urinary cytokines during intra ...... tability and prognostic value.
@en
P2093
Schamhart DH
de Boer EC
de Reijke TM
P304
P356
10.1097/00005392-199602000-00016
P407
P577
1996-02-01T00:00:00Z